- Conditions
- Dry Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- Surgical implantation of the CPCB-RPE1 implant
- Device
- Lead sponsor
- Regenerative Patch Technologies, LLC
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2040
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration, Age-related Macular Degeneration
- Interventions
- Pazopanib eye drops and Allergen Refresh Plus eye drops
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 30 Years to 55 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 2
- States / cities
- Fargo, North Dakota • Austin, Texas
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy, Non-neovascular AMD
- Interventions
- VOY-101
- Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Scottsdale, Arizona • Encino, California • Sacramento, California + 4 more
- Conditions
- Advanced Age-related Macular Degeneration
- Interventions
- LFG316
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 55 Years to 90 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Beverly Hills, California • Fort Myers, Florida + 5 more
- Conditions
- Age-related Macular Degeneration
- Interventions
- QA102, Placebo
- Drug
- Lead sponsor
- Smilebiotek Zhuhai Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Age-Related Macular Degeneration
- Interventions
- Palomid 529
- Drug
- Lead sponsor
- Paloma Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Macular Degeneration, Age-related, Geographic Atrophy
- Interventions
- BI 771716, Pegcetacoplan, Sham comparator to BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 46
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 42 more
- Conditions
- Geographic Atrophy
- Interventions
- BI 771716
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Walnut Creek, California • Jacksonville, Florida • Melbourne, Florida + 6 more
- Conditions
- Retinal Vascular Disorder, Macular Degeneration
- Interventions
- Not listed
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years to 115 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Advanced Dry Macular Degeneration
- Interventions
- Alpha MSH assay
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age-related Macular Degeneration
- Interventions
- carbidopa-levodopa 25-100 mg, placebo for carbidopa-levodopa 25-100 mg
- Drug
- Lead sponsor
- Snyder, Robert W., M.D., Ph.D., P.C.
- Individual
- Eligibility
- 50 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Age-related Macular Degeneration, Subfoveal Choroidal Neovascularization, Subretinal Scarring, Subretinal Fibrosis
- Interventions
- RXI-109
- Drug
- Lead sponsor
- RXi Pharmaceuticals, Corp.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
- Interventions
- observational study, VOY-101
- Other · Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 88 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Hippel-Lindau Disease
- Interventions
- EYE001
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- Not listed
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Age-Related Macular Degeneration
- Interventions
- MA09-hRPE
- Biological
- Lead sponsor
- Astellas Institute for Regenerative Medicine
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Miami, Florida • Boston, Massachusetts + 1 more
- Conditions
- Cataract, Macular Degeneration
- Interventions
- selenium, vitamin E, vitamin E placebo, selenium placebo
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 50 Years to 120 Years · Male only
- Enrollment
- 13,475 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2018
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Age Related Macular Degeneration
- Interventions
- Subretinally injected RetinoStat
- Drug
- Lead sponsor
- Oxford BioMedica
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 3
- States / cities
- Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
- Conditions
- Macular Degeneration, Choroidal Neovascularization
- Interventions
- Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)
- Drug
- Lead sponsor
- Light Sciences LLC
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Intermediate Age-Related Macular Degeneration
- Interventions
- Whole Egg - 4, Whole Egg - 2
- Drug
- Lead sponsor
- Kathryn Starr
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Age Related Cognitive Decline, Age Related Macular Degeneration
- Interventions
- Walnuts, habitual diet
- Dietary Supplement · Other
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 63 Years to 79 Years
- Enrollment
- 708 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Age-related Macular Degeneration
- Interventions
- Preventive Problem-Solving Training, Life and Health Review
- Behavioral
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Age-related Macular Degeneration, Geographic Atrophy
- Interventions
- VOY-101
- Biological
- Lead sponsor
- Perceive Biotherapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • Bellaire, Texas • Salt Lake City, Utah
- Conditions
- Age-Related Macular Degeneration, Geographic Atrophy
- Interventions
- Sirolimus
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 56 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Macular Degeneration
- Interventions
- BI 754132
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more